News
EXAS
54.20
-7.37%
-4.31
Exact Sciences: Strong Screening Revenue Growth and Strategic Initiatives Justify Buy Rating
TipRanks · 5h ago
Exact Sciences (EXAS) Gets a Buy from Bernstein
TipRanks · 1d ago
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Benzinga · 1d ago
Exact Sciences Price Target Maintained With a $65.00/Share by Benchmark
Dow Jones · 1d ago
Benchmark Reiterates Buy on Exact Sciences, Maintains $65 Price Target
Benzinga · 1d ago
Craig-Hallum Sticks to Their Buy Rating for Exact Sciences (EXAS)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Exact Sciences (EXAS) and Exelixis (EXEL)
TipRanks · 1d ago
Exact Sciences Boosts Finances and Plans New Launches
TipRanks · 1d ago
EXACT SCIENCES CORP - REVOLVING CREDIT AGREEMENT PERMITS BORROWINGS UP TO $500 MILLION
Reuters · 1d ago
EXACT SCIENCES CORP - ENTERS INTO SENIOR SECURED REVOLVING CREDIT AGREEMENT
Reuters · 1d ago
Analysts Conflicted on These Healthcare Names: Tilray (TLRY) and Exact Sciences (EXAS)
TipRanks · 1d ago
Stifel Nicolaus Remains a Buy on Exact Sciences (EXAS)
TipRanks · 1d ago
Exact Sciences (EXAS) Gets a Buy from TD Cowen
TipRanks · 1d ago
Exact Sciences: Strong Q4 Results and Promising Pipeline Justify Buy Rating
TipRanks · 2d ago
Exact Sciences’ Strong Q4 Performance and Growth Prospects Justify Buy Rating
TipRanks · 2d ago
Weekly Report: what happened at EXAS last week (0106-0110)?
Weekly Report · 2d ago
Exact Sciences expects Q4 and FY revenue to beat estimates
Seeking Alpha · 2d ago
Exact Sciences Reports Preliminary 2024 Results: Exepcts $2.76B In Annual Revenue (+10% YoY) And $713M In Q4 Revenue (+10% YoY)
Benzinga · 2d ago
Exact Sciences reports preliminary Q4 revenue $713M, consensus $694.76M
TipRanks · 2d ago
EXACT SCIENCES CORP - FULL-YEAR 2024 REVENUE EXPECTED TO INCREASE 10% TO $2.76 BILLION
Reuters · 2d ago
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.